CN108463222B - 用于治疗疾病的杂环化合物 - Google Patents

用于治疗疾病的杂环化合物 Download PDF

Info

Publication number
CN108463222B
CN108463222B CN201680078856.8A CN201680078856A CN108463222B CN 108463222 B CN108463222 B CN 108463222B CN 201680078856 A CN201680078856 A CN 201680078856A CN 108463222 B CN108463222 B CN 108463222B
Authority
CN
China
Prior art keywords
optionally substituted
formula
compounds
another embodiment
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680078856.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108463222A (zh
Inventor
拉朱·莫汉
约翰·努斯
詹森·哈里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oppilan Pharma Ltd USA
Original Assignee
Oppilan Pharma Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oppilan Pharma Ltd USA filed Critical Oppilan Pharma Ltd USA
Priority to CN202111183182.7A priority Critical patent/CN114149424B/zh
Publication of CN108463222A publication Critical patent/CN108463222A/zh
Application granted granted Critical
Publication of CN108463222B publication Critical patent/CN108463222B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680078856.8A 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物 Active CN108463222B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111183182.7A CN114149424B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255041P 2015-11-13 2015-11-13
US62/255,041 2015-11-13
PCT/US2016/061676 WO2017083756A1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111183182.7A Division CN114149424B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Publications (2)

Publication Number Publication Date
CN108463222A CN108463222A (zh) 2018-08-28
CN108463222B true CN108463222B (zh) 2021-10-22

Family

ID=58696139

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111183182.7A Active CN114149424B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物
CN201680078856.8A Active CN108463222B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202111183182.7A Active CN114149424B (zh) 2015-11-13 2016-11-11 用于治疗疾病的杂环化合物

Country Status (22)

Country Link
US (4) US10683291B2 (enExample)
EP (2) EP3373931B1 (enExample)
JP (3) JP6933384B2 (enExample)
KR (1) KR102720397B1 (enExample)
CN (2) CN114149424B (enExample)
AU (2) AU2016353348A1 (enExample)
BR (1) BR112018009745B1 (enExample)
CA (1) CA3005236C (enExample)
DK (1) DK3373931T3 (enExample)
ES (1) ES2932049T3 (enExample)
HR (1) HRP20221417T1 (enExample)
HU (1) HUE060594T2 (enExample)
IL (1) IL259297B2 (enExample)
LT (1) LT3373931T (enExample)
MX (1) MX382092B (enExample)
PL (1) PL3373931T3 (enExample)
PT (1) PT3373931T (enExample)
RS (1) RS63837B1 (enExample)
RU (1) RU2727194C2 (enExample)
SI (1) SI3373931T1 (enExample)
SM (1) SMT202300062T1 (enExample)
WO (1) WO2017083756A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3373931T3 (da) 2015-11-13 2022-11-28 Oppilan Pharma Ltd Heterocykliske forbindelser til behandling af sygdom
US20210163485A1 (en) * 2017-05-17 2021-06-03 Oppilan Pharma Ltd. Heterocyclic Compounds for the Treatment of Disease
EP3625230A1 (en) * 2017-05-17 2020-03-25 Oppilan Pharma Ltd. Prodrugs for the treatment of disease
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
EP4551573A1 (en) * 2022-07-06 2025-05-14 Oppilan Pharma Ltd. Crystalline forms of an s1p receptor modulator
CN120835886A (zh) * 2023-01-13 2025-10-24 奥比兰制药有限公司 S1p受体调节剂的制备

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184739A (zh) * 2005-06-08 2008-05-21 诺瓦提斯公司 多环二唑类和异唑类化合物及其作为s1p受体的配体的用途
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
CN103124727A (zh) * 2010-07-20 2013-05-29 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772597A (en) * 1983-10-14 1988-09-20 Pfizer Inc. 2-azacycloalkylthiopenem derivatives
EP1670463A2 (en) * 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
BRPI0612028A2 (pt) * 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
RU2425832C2 (ru) * 2006-04-03 2011-08-10 Астеллас Фарма Инк. Гетеросоединение
AU2007334436A1 (en) 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
WO2010117662A1 (en) 2009-03-30 2010-10-14 Exelixis, Inc. Modulators of s1p and methods of making and using
US9011494B2 (en) 2009-09-24 2015-04-21 Warsaw Orthopedic, Inc. Composite vertebral rod system and methods of use
PT2498611T (pt) 2009-11-13 2018-04-13 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral
AU2012325916A1 (en) 2011-10-20 2014-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
AU2014356967A1 (en) * 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
DK3373931T3 (da) 2015-11-13 2022-11-28 Oppilan Pharma Ltd Heterocykliske forbindelser til behandling af sygdom

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101184739A (zh) * 2005-06-08 2008-05-21 诺瓦提斯公司 多环二唑类和异唑类化合物及其作为s1p受体的配体的用途
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
CN103124727A (zh) * 2010-07-20 2013-05-29 百时美施贵宝公司 取代的3-苯基-1,2,4-噁二唑化合物

Also Published As

Publication number Publication date
JP2021191753A (ja) 2021-12-16
US20220227767A1 (en) 2022-07-21
EP4163281A1 (en) 2023-04-12
IL259297A (en) 2018-07-31
BR112018009745A8 (pt) 2019-02-26
JP2023017862A (ja) 2023-02-07
JP7445325B2 (ja) 2024-03-07
US20200325135A1 (en) 2020-10-15
RU2018121416A3 (enExample) 2019-12-17
KR102720397B1 (ko) 2024-10-21
HUE060594T2 (hu) 2023-03-28
RS63837B1 (sr) 2023-01-31
CN114149424A (zh) 2022-03-08
IL259297B2 (en) 2023-03-01
CA3005236C (en) 2024-02-20
RU2727194C2 (ru) 2020-07-21
BR112018009745B1 (pt) 2023-09-26
DK3373931T3 (da) 2022-11-28
US20190241556A1 (en) 2019-08-08
HRP20221417T1 (hr) 2023-02-03
EP3373931A4 (en) 2019-04-03
PL3373931T3 (pl) 2023-02-06
JP6933384B2 (ja) 2021-09-08
CN108463222A (zh) 2018-08-28
CA3005236A1 (en) 2017-05-18
AU2021202945B2 (en) 2022-06-23
MX382092B (es) 2025-03-04
SI3373931T1 (sl) 2023-02-28
AU2016353348A1 (en) 2018-07-05
RU2018121416A (ru) 2019-12-13
IL259297B (en) 2022-11-01
ES2932049T3 (es) 2023-01-09
MX2018005987A (es) 2018-11-29
BR112018009745A2 (pt) 2018-11-06
US10683291B2 (en) 2020-06-16
EP3373931B1 (en) 2022-09-28
LT3373931T (lt) 2023-03-10
CN114149424B (zh) 2025-05-13
PT3373931T (pt) 2022-12-06
AU2021202945A1 (en) 2021-06-03
JP2018535261A (ja) 2018-11-29
KR20180095811A (ko) 2018-08-28
JP7174963B2 (ja) 2022-11-18
WO2017083756A1 (en) 2017-05-18
SMT202300062T1 (it) 2023-03-17
US20230339944A1 (en) 2023-10-26
EP3373931A1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
CN108463222B (zh) 用于治疗疾病的杂环化合物
JP6076498B2 (ja) ナンセンス突然変異抑制剤としてのピリミド［４，５−ｂ］キノリン−４，５（３ｈ，１０ｈ）−ジオン
TW200911254A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
US11345713B2 (en) Compounds as modulators of TLR2 signaling
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
CN106414443B (zh) 吡啶并嘧啶二酮衍生物
WO2018211324A1 (en) Prodrugs for the treatment of disease
WO2018211323A1 (en) Hetercyclic compounds for the treatment of disease
HK40070316A (en) Heterocyclic compounds for the treatment of disease
JP7738924B2 (ja) 新規ｖｄａｃ１阻害剤
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease
US20210179583A1 (en) Inhibitors for the b-catenin/b-cell lymphoma 9 (bcl9) protein-protein interaction
HK1260375B (zh) 用於治疗疾病的杂环化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260375

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant